Special Issue

Cell Cycle Proteins as Promising Targets in Cancer Therapy

Message from the Guest Editor

The cell cycles in eukaryotic cells are dynamically regulated by extrinsic, growth factor-induced, mitogenic, and intrinsic signals from proteins that are involved in monitoring genomic integrity. Many human cancers harbor amplified genes encoding Cyclin D1, CDK4/6, and/or Cyclin E1, which function as drivers of oncogenesis. As many CDKs are frequently and aberrantly activated in human cancers, a rationale for targeting CDKs for cancer therapy has emerged that has culminated into the current clinical use of pharmacological inhibitors of CDK4/6 kinases, while a number of pharmacological inhibitors of CDKs, CHK1, PLK, and aurora kinases are being tested in clinical trials. With this Special Issue, we kindly invite our colleagues to submit their latest research findings or reviews covering new knowledge of the mechanisms and pathways involved in the regulation/control of cell cycles, as well as new knowledge of the regulation of mediators/transducers of cell cycles in cancer cells in in vitro and in vivo models. Papers describing novel inhibitors that target cell cycle transducers in basic and/or clinical settings are also welcomed.

Guest Editor

Prof. Arun K. Rishi

Department of Oncology, School of Medicine, Wayne State University, Detroit, MI 48201, USA

Deadline for manuscript submissions

closed (30 April 2022)



Cancers

an Open Access Journal by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



mdpi.com/si/73415

Cancers
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
cancers@mdpi.com

mdpi.com/journal/cancers





Cancers

an Open Access Journal by MDPI

Impact Factor 4.4 CiteScore 8.8 Indexed in PubMed



About the Journal

Message from the Editor-in-Chief

Cancers is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Editor-in-Chief

Prof. Dr. Samuel C. Mok.

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)

